Replies to post #170225 on Biotech Values

[mcbio]

(VRTX)—I doubt that JNJ will get much of a return on that $152M investment.

Seems surprising to me that JNJ would do this given simeprevir near likely widespread approval not to mention obviously all of the other very promising HCV drugs (beyond PI class) that will likely render Incivo soon obsolete. Good deal for VRTX me thinks.